PMID- 17117175
OWN - NLM
STAT- MEDLINE
DCOM- 20070122
LR  - 20220216
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 95
IP  - 11
DP  - 2006 Dec 4
TI  - Effect of treatment with epoetin beta on short-term tumour progression and 
      survival in anaemic patients with cancer: A meta-analysis.
PG  - 1467-73
AB  - To assess the early effect of epoetin beta on survival and tumour progression in 
      anaemic patients with cancer, data were pooled from nine randomised clinical 
      trials comparing epoetin beta with placebo or standard care. Studies were not 
      primarily designed to assess these end points. Follow-up was for treatment 
      duration plus 4 weeks following therapy completion. All adverse events (AEs) were 
      retrospectively reviewed blinded, for progression. Thromboembolic events were 
      also assessed. Data analysis involved standard statistical tests. Overall, 1413 
      patients were included (epoetin beta, n = 800; control, n = 613; 56% 
      haematological, and 44% solid). Median initial epoetin beta dose was 30,000 
      IU/week. Overall survival during months 0-6 was similar with epoetin beta and 
      control (0.31 vs 0.32 deaths/patient-year). No increased mortality risk was seen 
      with epoetin beta (relative risk (RR) 0.97, 95% CI: 0.69, 1.36; P = 0.87). There 
      was a significantly reduced risk of rapidly progressive disease for epoetin beta 
      (RR 0.78, 95% CI: 0.62, 0.99; P = 0.042). Epoetin beta was associated with a 
      slightly higher frequency of thromboembolic events vs control (5.9% vs 4.2% of 
      patients) but thromboembolic-related mortality was identical in both groups 
      (1.1%). Epoetin beta provided a slight beneficial effect on tumour progression 
      and did not impact on early survival or thromboembolic-related mortality.
FAU - Aapro, M
AU  - Aapro M
AD  - Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, 1, route du Muids, 
      CH-1272 Genolier, Switzerland. maapro@genolier.net
FAU - Coiffier, B
AU  - Coiffier B
FAU - Dunst, J
AU  - Dunst J
FAU - Osterborg, A
AU  - Osterborg A
FAU - Burger, H U
AU  - Burger HU
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20061121
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Recombinant Proteins)
RN  - 0 (epoetin beta)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/*drug therapy
MH  - Disease Progression
MH  - Erythropoietin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*mortality
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Proteins
MH  - Survival Rate
PMC - PMC2360728
EDAT- 2006/11/23 09:00
MHDA- 2007/01/24 09:00
PMCR- 2007/12/04
CRDT- 2006/11/23 09:00
PHST- 2006/11/23 09:00 [pubmed]
PHST- 2007/01/24 09:00 [medline]
PHST- 2006/11/23 09:00 [entrez]
PHST- 2007/12/04 00:00 [pmc-release]
AID - 6603481 [pii]
AID - 10.1038/sj.bjc.6603481 [doi]
PST - ppublish
SO  - Br J Cancer. 2006 Dec 4;95(11):1467-73. doi: 10.1038/sj.bjc.6603481. Epub 2006 
      Nov 21.